Annual accounts receivable:
$601.99M+$201.66M(+50.37%)Summary
- As of today (May 29, 2025), SRPT annual accounts receivable is $601.99 million, with the most recent change of +$201.66 million (+50.37%) on December 31, 2024.
- During the last 3 years, SRPT annual accounts receivable has risen by +$449.00 million (+293.48%).
- SRPT annual accounts receivable is now at all-time high.
Performance
SRPT Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$659.37M+$57.38M(+9.53%)Summary
- As of today (May 29, 2025), SRPT quarterly accounts receivable is $659.37 million, with the most recent change of +$57.38 million (+9.53%) on March 1, 2025.
- Over the past year, SRPT quarterly accounts receivable has increased by +$280.56 million (+74.07%).
- SRPT quarterly accounts receivable is now at all-time high.
Performance
SRPT Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
SRPT Accounts receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +50.4% | +74.1% |
3 y3 years | +293.5% | +270.0% |
5 y5 years | +565.9% | +633.0% |
SRPT Accounts receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +293.5% | at high | +270.0% |
5 y | 5-year | at high | +565.9% | at high | +633.0% |
alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
SRPT Accounts receivable History
Date | Annual | Quarterly |
---|---|---|
Mar 2025 | - | $659.37M(+9.5%) |
Dec 2024 | $601.99M(+50.4%) | $601.99M(+38.5%) |
Sep 2024 | - | $434.52M(+20.7%) |
Jun 2024 | - | $360.00M(-5.0%) |
Mar 2024 | - | $378.81M(-5.4%) |
Dec 2023 | $400.33M(+86.5%) | $400.33M(+25.6%) |
Sep 2023 | - | $318.86M(+34.6%) |
Jun 2023 | - | $236.81M(+5.8%) |
Mar 2023 | - | $223.84M(+4.3%) |
Dec 2022 | $214.63M(+40.3%) | $214.63M(+6.5%) |
Sep 2022 | - | $201.51M(-1.2%) |
Jun 2022 | - | $203.85M(+14.4%) |
Mar 2022 | - | $178.19M(+16.5%) |
Dec 2021 | $152.99M(+51.7%) | $152.99M(+2.5%) |
Sep 2021 | - | $149.32M(+17.5%) |
Jun 2021 | - | $127.05M(+7.9%) |
Mar 2021 | - | $117.73M(+16.7%) |
Dec 2020 | $100.87M(+11.6%) | $100.87M(-3.5%) |
Sep 2020 | - | $104.49M(+10.3%) |
Jun 2020 | - | $94.69M(+5.3%) |
Mar 2020 | - | $89.96M(-0.5%) |
Dec 2019 | $90.41M(+87.4%) | $90.41M(+34.4%) |
Sep 2019 | - | $67.26M(+19.7%) |
Jun 2019 | - | $56.19M(+13.0%) |
Mar 2019 | - | $49.72M(+3.0%) |
Dec 2018 | $48.25M(+69.1%) | $48.25M(+0.9%) |
Sep 2018 | - | $47.81M(+13.7%) |
Jun 2018 | - | $42.06M(+8.1%) |
Mar 2018 | - | $38.92M(+36.4%) |
Dec 2017 | $28.54M(+445.9%) | $28.54M(+15.3%) |
Sep 2017 | - | $24.75M(+39.1%) |
Jun 2017 | - | $17.79M(+44.9%) |
Mar 2017 | - | $12.28M(+134.9%) |
Dec 2016 | $5.23M(+31.5%) | $5.23M(+31.2%) |
Sep 2016 | - | $3.99M(+0.1%) |
Jun 2016 | - | $3.98M(-0.2%) |
Mar 2016 | - | $3.99M(+0.3%) |
Dec 2015 | $3.98M | $3.98M(+45.5%) |
Sep 2015 | - | $2.73M(+13.1%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2015 | - | $2.42M(0.0%) |
Mar 2015 | - | $2.42M(0.0%) |
Dec 2014 | $2.42M(-31.6%) | $2.42M(-28.1%) |
Sep 2014 | - | $3.36M(-35.7%) |
Jun 2014 | - | $5.23M(-33.4%) |
Mar 2014 | - | $7.85M(+122.4%) |
Dec 2013 | $3.53M(-25.1%) | $3.53M(-47.5%) |
Sep 2013 | - | $6.72M(+77.4%) |
Jun 2013 | - | $3.79M(-33.0%) |
Mar 2013 | - | $5.65M(+19.9%) |
Dec 2012 | $4.71M(+29.7%) | $4.71M(+90.5%) |
Sep 2012 | - | $2.47M(-65.5%) |
Jun 2012 | - | $7.18M(+39.8%) |
Mar 2012 | - | $5.13M(+41.3%) |
Dec 2011 | $3.63M(+12.7%) | $3.63M(-14.9%) |
Sep 2011 | - | $4.27M(-60.8%) |
Jun 2011 | - | $10.89M(-19.8%) |
Mar 2011 | - | $13.58M(+321.1%) |
Dec 2010 | $3.22M(+54.6%) | $3.22M(-38.5%) |
Sep 2010 | - | $5.24M(+143.4%) |
Jun 2010 | - | $2.15M(+30.6%) |
Mar 2010 | - | $1.65M(-21.0%) |
Dec 2009 | $2.08M(-58.1%) | $2.08M(-63.2%) |
Sep 2009 | - | $5.67M(+68.8%) |
Jun 2009 | - | $3.36M(+7.5%) |
Mar 2009 | - | $3.13M(-37.1%) |
Dec 2008 | $4.97M(+73.2%) | $4.97M(+21.9%) |
Sep 2008 | - | $4.08M(+52.9%) |
Jun 2008 | - | $2.67M(-34.2%) |
Mar 2008 | - | $4.05M(+41.2%) |
Dec 2007 | $2.87M(+5472.4%) | $2.87M(+63.9%) |
Sep 2007 | - | $1.75M(+56.4%) |
Jun 2007 | - | $1.12M(+102.9%) |
Mar 2007 | - | $551.80K(+971.5%) |
Dec 2006 | $51.50K(-95.8%) | $51.50K(-16.0%) |
Sep 2006 | - | $61.30K(+38.1%) |
Jun 2006 | - | $44.40K(-94.7%) |
Mar 2006 | - | $840.20K(-32.0%) |
Dec 2005 | $1.24M | $1.24M |
FAQ
- What is Sarepta Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual accounts receivable year-on-year change?
- What is Sarepta Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly accounts receivable year-on-year change?
What is Sarepta Therapeutics annual accounts receivable?
The current annual accounts receivable of SRPT is $601.99M
What is the all time high annual accounts receivable for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual accounts receivable is $601.99M
What is Sarepta Therapeutics annual accounts receivable year-on-year change?
Over the past year, SRPT annual accounts receivable has changed by +$201.66M (+50.37%)
What is Sarepta Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of SRPT is $659.37M
What is the all time high quarterly accounts receivable for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly accounts receivable is $659.37M
What is Sarepta Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, SRPT quarterly accounts receivable has changed by +$280.56M (+74.07%)